|
[1]SUNDARAM V,KOWDLEY K.Management of chronic hepatitis B infection[J].BMJ,2015,351:h4263.
|
|
[2]WANG WB,ZHANG H,PETZOLD M,et al.Cost-effectiveness of the Health X Project for tuberculosis control in China[J].Int J Tuberc Lung Dis,2014,18(8):939-945.
|
|
[3]KARALIAN MA.The influence of chronic viral infections on tuberculosis[J].Georgian Med News,2009,168(1):63-67.
|
|
[4]SHARMA P,TYAGI P,SINGLA V,et al.Clinical and biochemical profile of tuberculosis in patients with liver cirrhosis[J].J Clin Exp Hepatol,2015,5(1):8-13.
|
|
[5]LIU YM,CHENG YJ,LI YL,et al.Antituberculosis treatment and hepatotoxicity in patients with chronic viral hepatitis[J].Lung,2014,192(1):205-210.
|
|
[6]Chinese Society of Hepatology,Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:2015 update[J].J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960.
|
|
[7]World Health Organization.Global Tuberculosis Report 2015[R].Switzerland:World Health Organization,2015.
|
|
[8]YU R,FAN R,HOU J.Chronic hepatitis B virus infection:epidemiology,prevention,and treatment in China[J].Front Med,2014,8(2):135-144.
|
|
[9]BLIVEN EE,PODEWILS LJ.The role of chronic hepatitis in isoniazid hepatotoxicity during treatment for latent tuberculosis infection[J].Int J Tuberc Lung Dis,2009,13(9):1054-1060.
|
|
[10]WANG JY,LIU CH,HU FC,et al.Risk factors of hepatitis during anti-tuberculous treatment and implications of hepatitis virus load[J].J Infect,2011,62(6):448-455.
|
|
[11]MIYAZAWA S,MATSUOKA S,HAMANA S,et al.Isoniazid-induced acute liver failure during preventive therapy for latent tuberculosis infection[J].Intern Med,2015,54(6):591-595.
|
|
[12]PENG YC,LIN CL,KAO CH.Increased risk of liver cirrhosis for tuberculosis infection:response to Shen[J].Eur J Clin Invest,2015,45(9):1001-1002.
|
|
[13]JAIN D,AGGARWAL HK,JAIN P,et al.Primary hepatic tuberculosis presenting as acute liver failure[J].Oxf Med Case Reports,2014,2014(9):153-155.
|
|
[14]GUO HY,LIU HB,ZHANG CG.Immune response of T lymphocytes in patients with pulmonary tuberculosis combine with chronic hepatitis B[J].Chin J Infect Control,2010,9(1):19-24.(in Chinese)郭皓宇,刘洪波,张成国.肺结核合并慢性乙型肝炎患者T淋巴细胞免疫应答研究[J].中国感染控制杂志,2010,9(1):19-24.
|
|
[15]ZHENG YX,MA SJ,TAN DM,et al.A meta-analysis of liver lesions in hepatitis B patients undergoing anti-tuberculosis therapy[J].Chin J Hepatol,2014,22(8):585-589.(in Chinese)郑宜翔,马淑娟,谭德明,等.乙型肝炎患者抗结核治疗时肝损害的Meta分析[J].中华肝脏病杂志,2014,22(8):585-589.
|
|
[16]YI D,CHENG SQ.Expression and role of Toll-like receptor in chronic hepatitis B[J].Acta Med Sin,2015,28(5):171-174.(in Chinese)易丹,程书权.TOLL样受体在慢性乙型肝炎中的表达及作用[J].华夏医学,2015,28(5):171-174.
|
|
[17]HARDING CW.Regulation of antigen presentation by mycobacterium tuberculosis:a role for Toll-like receptors[J].Nat Rev Microbiol,2010,8(4):296-307.
|
|
[18]TAN G,ZHAO W,LIU X,et al.Immunophenotypic profile of intrahepatic and circulating lymphocytes in chronic hepatitis B patients[J].Hepatogastroenterology,2012,59(117):1516-1521.
|
|
[19]SHIMIZU Y.T cell immunopathogenesis and immunotherapeutic strategies for chronic hepatitis B virus infection[J].World J Gastroenterol,2012,18(20):2443-2451.
|
|
[20]BONI C,FISICARO P,VALDATTA C,et al.Characterization of hepatitis B virus(HBV)-specific T-cell dysfunction in chronic HBV infection[J].J Virol,2007,81(8):4215-4225.
|
|
[21]CHEN Y,LI X,YE B,et al.Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B[J].Antiviral Research,2011,91(1):23-31.
|
|
[22]CHEN TB,FAN GR,LI J,et al.T lymphocyte subsets in peripheral blood of chronic hepatitis B and its clinical significance[J].Chin J Cell Mol Immunol,2010,26(9):912-913.(in Chinese)陈天宝,范公忍,李娟,等.慢性乙型肝炎外周血T淋巴细胞亚群变化及其临床意义[J].细胞与分子免疫学杂志,2010,26(9):912-913.
|
|
[23]WINSLOW GM,COOPER A,REILEY W,et al.Early T-cell responses in tuberculosis immunity[J].Immunol Rev,2008,225(1):284-299.
|
|
[24]WIKER HG,MUSTAFA T,BJUNE GA,et al.Evidence for waning of latency in a cohort study of tuberculosis[J].BMC Infect Dis,2010,37(10):1-10.
|
|
[25]GUO S,ZHAO J.Immunotherapy for tuberculosis:what's the better choice?[J].Front Biosci(Landmark Ed),2012,17(1):2684-2690.
|
|
[26]YU ML,GUO HX,WANG YX,et al.The dynamic changes of tuberculosis related eytokines during disease progression[J].Chin J Tuberc Respir Dis,2015,38(8):584-588.(in Chinese)余美玲,郭卉欣,王云霞,等.肺结核患者体内结核病相关免疫细胞因子的动态变化[J].中华结核和呼吸杂志,2015,38(8):584-588.
|
|
[27]YUE LM,QIN JL,WANG CF,et al.Advances on Th1/Th2 balance in the mycobacterium tuberculosis immunity[J].Chin J Immunol,2015,31(10):1426-1429.(in Chinese)岳丽敏,秦峻岭,王春芳,等.Th1/Th2平衡在结核分枝杆菌免疫中的研究进展[J].中国免疫学杂志,2015,31(10):1426-1429.
|
|
[28]TAN Q,XIE WP,MIN R,et al,Characterization of Th1 and Th2-type immune response in human multidrug-resistant tuberculosis[J].Eur J Clin Microbiol Infect Dis,2012,31(6):1233-1242.
|
|
[29]LI DR,YANG YH,ZHU GY,et al.Studies on interferon gamma for tuberculous pleurisy adjuvant treatment and the expression of nature kill T cell[J].World Clin Drugs,2015,36(9):596-599.(in Chinese)李登瑞,杨永辉,朱桂云,等.γ-干扰素辅助治疗结核性胸膜炎及自然杀伤T细胞表达研究[J].世界临床药物,2015,36(9):596-599.
|
|
[30]LI JN,LI ZX,REN L,et al.The clinical efficacy of lamivudine treatment smear positive pulmonary tuberculosis and hepatitis B virus carriers and on T lymphocytes[J].Chin J Prim Med Pharm,2015,22(2):295-297.(in Chinese)厉景南,李朝霞,任琅,等.拉米夫定治疗初治涂阳肺结核合并乙肝病毒携带者的临床疗效及对T淋巴细胞的影响[J].中国基层医药,2015,22(2):295-297.
|
|
[31]HU JH,CHENG SQ,TANG ZX,et al.Research on clinicaland pathological hanges of chronic hepatitis B patiens infected with different HBV genotypes[J].J Chongqing Med Univ,2012,37(4):355-359.(in Chinese)胡金华,程书权,唐振祥,等.不同基因型HBV感染的慢性乙型肝炎患者临床与病理改变研究[J].重庆医科大学学报,2012,37(4):355-359.
|
|
[32]WANG JY,HU JH,CHENG SQ.Hepatic pathological and clinical relationship in early cirrhosispatients infected with different HBV genotypes[J].J Chongqing Med Univ,2013,38(8):939-942.(in Chinese)王继业,胡金华,程书权.不同基因类型HBV感染早期肝硬化患者肝脏病理与临床的关系[J].重庆医科大学学报,2013,38(8):939-942.
|
|
[33]WANG H,XUE L,YAN R,et al.Comparison of histologic characteristics of chinese chronic hepatitis B patients with persistently normal or mildly elevated ALT[J].PLoS One,2013,8(11):e80585.
|
|
[34]PENG YC,LIN CL,HSU WY,et al.Risk of liver cirrhosis in patients with tuberculosis:a nationwide cohort study[J].Eur J Clin Invest,2015,45(7):663-669.
|
|
[35]SMYK D,RIGOPOULOU E I,ZEN Y,et al.Role for mycobacterial infection in pathogenesis of primary biliary cirrhosis?[J].World J Gastroenterol,2012,18(35):4855-4865.
|
|
[36]LIN YT,WU PH,LIN CY.Cirrhosis as a risk factor for tuberculosis infection-a nationwide longitudinal study in Taiwan[J].Am J Epidemiol,2014,180(1):103-110.
|
|
[37]CHENG SQ.A study of 172 patiens with hepatic injury caused by antituberculosis drugs[J].Chin J Hepatol,2004,12(9):571-573.(in Chinese)程书权.抗结核药物致肝损害172例临床分析[J].中华肝脏病杂志,2004,12(9):571-573.
|
|
[38]KHARRASSE G,SOUFI M,BEREKHLI H,et al.Primary tuberculoma of the liver:a case report and literature review[J].Pan Afr Med J,2014,19:321.
|
|
[39]SAITOU Y,HATAZI O,AONUMA H,et al.Pulmonary tuberculoma in a patient with chronic hepatitis C:a clinical pitfall in the treatment strategy[J].Intern Med,2014,53(15):1669-1674.
|
|
[40]DEVARBHAVI H,SINGH R,PATIL M,et al.Outcome and determinants of mortality in 269 patients with combination anti-tuberculosis drug-induced liver injury[J].J Gastroenterol Hepatol,2013,28(1):161-167.
|
|
[41]CHANG ZD.Clinical observation on liver function impairment caused by anti-tuberculosis treatment in patients with positive HBsA g[J].Modern Preven Med,2013,40(5):950-952.(in Chinese)常振东.抗结核药物对乙肝表面抗原阳性肺结核患者肝功能影响的临床观察[J].现代预防医学,2013,40(5):950-952.
|
|
[42]WANG SJ.Efficacy of retreatmentα-interferon in combination with chemotherapy in the treatment of tuberculosis associated with hepatitis B[J].Shandong Med,2007,47(19):159.(in Chinese)王守京.α-干扰素联合化疗治疗伴发乙肝的复治肺结核疗效观察[J].山东医药,2007,47(19):159.
|
|
[43]CAI HD.HBV antiviral concurrent tuberculosis need refinement[J].PLA Health,2012,1:27.(in Chinese)蔡晧东.乙肝并发肺结核抗病毒需细化[J].解放军健康,2012,1:27.
|
|
[44]ZHAO YH,YU JW,LI SC.Observation of clinical efficacy of preventing liver injury of lamivudine on hepatitis B virus carriers with anti-tuberculosis drugs[J].Chin J Infect Dis,2007,25(5):303-306.(in Chinese)赵勇华,于建武,李树臣.拉米夫定预防乙型肝炎病毒携带者抗结核治疗致肝损伤的临床疗效[J].中华传染病杂志,2007,25(5):303-306.
|
|
[45]JIANG J,ZHANG JC,DING DS,et al.Clinical emcacy of adefovir dipivoxil combined with anti-tuberculosis drugs inn treatment for chronic hepatitis B complicated with pulmonary tuberculosis[J].Chin J Gen Pract,2009,8(3):160-162.(in Chinese)姜捷,张建春,丁登森,等.抗结核同时给予阿德福韦酯治疗慢性乙型肝炎合并肺结核的临床疗效[J].中华全科医师杂志,2009,8(3):160-162.
|
|
[46]WANG SQ,WEI W.Silibinin and telbivudine joint prevention of hepatitis B virus carriers in TB treatment effect of liver damage[J].Chin J Prevent Control Chronic No-Communicable,2015,23(2):133-135.(in Chinese)王三清,魏魏.水飞蓟宾与替比夫定联合在预防乙型肝炎病毒携带者抗结核治疗肝损害中的效果[J].中国慢性病预防与控制,2015,23(2):133-135.
|
|
[47]GUO XH,LIU Y.Effect of entecavir on the liver function of tuberculosis patients with HBV DNA positive[J].Chin J Hosp Pharm,2014,34(3):226-228.(in Chinese)郭晓红,刘颖.恩替卡韦对乙型肝炎病毒DNA阳性肺结核患者肝功能干预的作用[J].中国医院药学杂志,2014,34(3):226-228.
|
|
[48]CLERCQ ED.Current treatment of hepatitis B virus infections[J].Reve Med Virol,2015,25(6):354-365.
|
|
[49]LO HY,SUO J,CHANG HJ,et al.Risk factors associated with death in a 12-month cohort analysis of tuberculosis patients:12-month follow-up after registration[J].Asia Pac J Public Health,2015,27(2):758-768.
|
|
[50]CHENG SQ,HU JH,NI H,et al.Clinical analysisα-interferon combined with mannan peptiede teatment of chronic hepatitis B patiens in different gene type[J].Clin Focus,2010,29(20):1749-1754.(in Chinese)程书权,胡金华,倪辉,等.不同基因类型慢性乙型肝炎患者对α干扰素联合甘露聚糖肽治疗的临床研究[J].临床荟萃,2010,29(20):1749-1754.
|
PDF下载 ( 1873 KB)
本文二维码
下载:
